Aurinia Pharmaceuticals Inc
AUPH11.350USD
+0.090+0.80%
收盘 10/03, 16:00（美东）报价延迟15分钟
1.51B总市值
24.83市盈率 TTM
关于 Aurinia Pharmaceuticals Inc 公司
Aurinia Pharmaceuticals Inc. 是一家完全整合的生物制药公司。该公司专注于为患有自身免疫性疾病且医疗需求尚未得到满足的患者提供治疗。该公司已开发出 LUPKYNIS（voclosporin），这是一种用于治疗活动性狼疮性肾炎 (LN) 成人患者的口服疗法，并继续开展临床和监管活动以支持 LUPKYNIS 开发计划。该公司主要致力于开发其管线资产 AUR200，这是一种针对 BAFF（B 细胞活化因子）和 APRIL（增殖诱导配体）的差异化、潜在的下一代自身免疫性疾病疗法。该公司与大塚制药株式会社 (Otsuka) 签订了合同，作为合作伙伴在大塚地区开发和商业化 LUPKYNIS。该公司主要向专科药房和专科分销商以及其美国以外的合作伙伴大塚销售 LUPKYNIS（voclosporin）。
Aurinia Pharmaceuticals Inc简介
公司代码AUPH
公司名称Aurinia Pharmaceuticals Inc
上市日期Jul 16, 2001
CEOMr. Peter S. Greenleaf
员工数量130
证券类型Ordinary Share
年结日Jul 16
公司地址#140, 14315 - 118 Avenue
城市EDMONTON
上市交易所NASDAQ Global Market Consolidated
国家Canada
邮编T5L 4S6
电话12507442487
网址https://www.auriniapharma.com
公司代码AUPH
上市日期Jul 16, 2001
CEOMr. Peter S. Greenleaf
Aurinia Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Craig Johnson
Mr. Craig Johnson
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
收入明细
单位: USD更新时间: 10月2日 周四
单位: USD更新时间: 10月2日 周四
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
US
210.09M
89.35%
Japan
25.04M
10.65%
Other
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月17日 周日
更新时间: 8月17日 周日
持股股东
股东类型
持股股东
持股股东
占比
Tang Capital Management, LLC
7.62%
ILJIN SNT Co., Ltd.
4.96%
BlackRock Institutional Trust Company, N.A.
4.91%
New Enterprise Associates (NEA)
3.02%
State Street Global Advisors (US)
2.12%
其他
77.37%
持股股东
持股股东
占比
Tang Capital Management, LLC
7.62%
ILJIN SNT Co., Ltd.
4.96%
BlackRock Institutional Trust Company, N.A.
4.91%
New Enterprise Associates (NEA)
3.02%
State Street Global Advisors (US)
2.12%
其他
77.37%
股东类型
持股股东
占比
Investment Advisor
13.16%
Hedge Fund
12.86%
Investment Advisor/Hedge Fund
12.24%
Corporation
4.96%
Venture Capital
3.02%
Research Firm
2.52%
Individual Investor
2.49%
Pension Fund
0.74%
Bank and Trust
0.31%
其他
47.69%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
429
59.45M
45.16%
-10.76M
2025Q2
446
77.42M
58.75%
-1.04M
2025Q1
457
75.49M
55.51%
-3.25M
2024Q4
454
71.04M
51.53%
-9.95M
2024Q3
449
70.86M
49.85%
-8.98M
2024Q2
452
69.33M
48.80%
-9.83M
2024Q1
446
69.12M
48.16%
-8.26M
2023Q4
460
67.04M
46.69%
-7.24M
2023Q3
469
63.17M
44.06%
-14.31M
2023Q2
493
65.34M
45.61%
-23.55M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Tang Capital Management, LLC
10.03M
7.62%
--
--
Jun 30, 2025
ILJIN SNT Co., Ltd.
6.54M
4.96%
-984.75K
-13.10%
Aug 12, 2025
BlackRock Institutional Trust Company, N.A.
6.46M
4.91%
-1.01M
-13.48%
Jun 30, 2025
New Enterprise Associates (NEA)
3.97M
3.02%
--
--
Jun 30, 2025
State Street Global Advisors (US)
2.80M
2.12%
-56.08K
-1.97%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.70M
1.29%
-36.55K
-2.10%
Jun 30, 2025
The Vanguard Group, Inc.
1.69M
1.29%
-250.93K
-12.90%
Jun 30, 2025
Armistice Capital LLC
1.63M
1.24%
-3.37M
-67.41%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.58M
1.2%
-157.24K
-9.07%
Jun 30, 2025
Qube Research & Technologies Ltd
1.24M
0.94%
+386.36K
+45.13%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月2日 周四
更新时间: 10月2日 周四
机构名称
占比
Virtus LifeSci Biotech Products ETF
2.43%
Janus Henderson Small Cap Growth Alpha ETF
2.01%
ALPS Medical Breakthroughs ETF
0.95%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.2%
SPDR S&P International Small Cap ETF
0.19%
Vanguard US Multifactor ETF
0.18%
ProShares Ultra Nasdaq Biotechnology
0.17%
Invesco Nasdaq Biotechnology ETF
0.16%
Avantis US Small Cap Equity ETF
0.14%
iShares Biotechnology ETF
0.14%
查看更多
Virtus LifeSci Biotech Products ETF
占比2.43%
Janus Henderson Small Cap Growth Alpha ETF
占比2.01%
ALPS Medical Breakthroughs ETF
占比0.95%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
占比0.2%
SPDR S&P International Small Cap ETF
占比0.19%
Vanguard US Multifactor ETF
占比0.18%
ProShares Ultra Nasdaq Biotechnology
占比0.17%
Invesco Nasdaq Biotechnology ETF
占比0.16%
Avantis US Small Cap Equity ETF
占比0.14%
iShares Biotechnology ETF
占比0.14%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
